Protein– tag –
-
Biogen’s Salanersen Granted FDA Breakthrough Therapy Designation for SMA Patients with Suboptimal Gene Therapy Response
Cure SMA USA Overview Biogen's investigational spinal muscular atrophy (SMA) therapy, salanersen, has received Breakthrough Therapy Designation from the FDA. This designation is based on promising Phase 1b data in pediatric SMA patients ... -
Biologically-Driven Generative Chemistry: Advanced Deep Generative Models for De Novo Drug Design
ChemRxiv International Overview A new preprint study reviews biologically-driven generative chemistry, emphasizing deep generative models for novel molecular design. These models now integrate diverse biological data, including bioassays... -
Isomorphic Labs Secures $2.1B Series B Funding to Scale AI Drug Discovery Platform ‘IsoDDE’
IntuitionLabs UK Overview Isomorphic Labs, a Google DeepMind spin-off, has successfully raised $2.1 billion in Series B funding to globally expand its AI-driven drug discovery platform, 'IsoDDE,' and advance multiple drug programs. Built... -
AI Propels Drug Discovery with Breakthroughs in Protein Structure Prediction and Generative Molecular Design
AI Medicine Today USA Overview Artificial intelligence is dramatically accelerating drug discovery across multiple stages, from target identification to clinical trial optimization. DeepMind's AlphaFold has revolutionized protein structu... -
Novel Anti-Cancer Vaccine Targeting Neuroblastoma Achieves Early Success with Peptide Nanoparticles, Paving Way for GPC2-Targeted Immunotherapy
EurekAlert! USA Overview Researchers have achieved early success in developing a new anti-cancer vaccine specifically targeting neuroblastoma. This groundbreaking vaccine is based on self-assembling microscopic particles known as peptide... -
Reliability of AI Antibody Design Hinges on Training Data: AlphaFold Era Highlights Data Quality Challenge
Drug Discovery News USA Overview Advancements in protein AI, such as AlphaFold, have ushered in a new computational era for antibody discovery, enabling predictions of protein folding and interactions with near-experimental accuracy. How... -
FDA Streamlines Nonclinical Studies for Biologics and Conjugated Products, Accepting NAMs for ADCs to Reduce Non-Human Primate Use
FDA USA Overview The FDA's Center for Drug Evaluation and Research (CDER) is streamlining nonclinical studies for biologics and conjugated products, including Antibody-Drug Conjugates (ADCs) and CD3 bispecific T-cell engagers. For ADCs w... -
Imperial College London’s DeCAF-Pearl AI Model Enables Practical Large-Scale Molecular Screening, Surpassing AlphaFold 3 Efficiency
Imperial College London UK Overview Researchers at Imperial College London, in collaboration with the Genesis Research Team, have developed DeCAF-Pearl, a new AI model based on flow maps that makes large-scale molecular screening practic... -
UVA’s YuelDesign AI Framework Models Protein Flexibility for Improved Drug Design, Demonstrating Success on CDK2 Target
IntuitionLabs USA Overview The YuelDesign framework, developed by a UVA team, represents a significant advancement in structure-based drug design by explicitly modeling protein flexibility during ligand generation using AI diffusion mode... -
Latent Labs’ Generative AI Transforms Molecular Design, Producing Macrocyclic Peptides and Antibody Candidates in Weeks
CVPR (Computer Vision and Pattern Recognition) USA Overview Latent Labs, through its Latent-X1 and Latent-Y platforms, is transforming drug discovery by enabling de novo molecular design from intent, rather than traditional library scree...
